Compaq Biopharmaceutical Technology

Compaq Biopharmaceutical Technology is a China-based biotechnology company focused on the development of innovative therapeutic agents for oncology and other high-unmet-need areas. The company specializes in the research and development of monoclonal antibodies and small molecule inhibitors targeting key pathways in cancer progression, such as PD-1 and VEGF. Compaq Biopharmaceutical operates research facilities in Beijing and is actively advancing several candidates through clinical trials in China. Their business model encompasses the entire drug development lifecycle, from discovery and preclinical validation to clinical evaluation and potential commercialization.